QURE uniQure N.V.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1590560 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY28.0%
TTM net income YoY1.0%
TTM EPS YoY20.2%
Revenue 3-yr CAGR-43.5%
Net income 3-yr CAGR—
Margins
Gross margin93.9%
Operating margin-1,001.7%
Net margin-1,154.8%
FCF margin-956.8%
EBITDA margin-921.0%
Returns
ROE-89.0%
ROA-25.5%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets68.7%
Debt / equity0.17x
Current ratio11.52x
Interest coverage-3.51x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue3.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $16.10M | $27.12M |
| Cost of revenue | $1.69M | $1.27M |
| Gross profit | $14.41M | $25.85M |
| R&D expense | $140.67M | $143.78M |
| SG&A expense | $65.46M | $52.66M |
| Operating income | -$185.35M | -$184.29M |
| Interest expense | $61.99M | $63.74M |
| Pretax income | -$193.34M | -$237.13M |
| Income tax | $5.63M | $2.43M |
| Net income | -$198.97M | -$239.56M |
| EBITDA | -$170.59M | -$171.65M |
| EPS (basic) | -3.46 | -4.92 |
| EPS (diluted) | -3.46 | -4.92 |
| Weighted avg. shares (diluted) | 57.50M | 48.65M |
| Balance sheet | ||
| Cash & equivalents | $80.24M | $160.33M |
| Receivables | $5.86M | — |
| Current assets | $655.99M | $390.29M |
| PP&E, net | $13.80M | $20.42M |
| Goodwill | $25.36M | $22.41M |
| Intangibles | $72.79M | $71.04M |
| Total assets | $824.91M | $556.54M |
| Current liabilities | $62.92M | $40.05M |
| Long-term debt | $49.70M | $51.32M |
| Total debt | $49.70M | $51.32M |
| Total liabilities | $626.01M | $563.29M |
| Shareholders' equity | $198.90M | -$6.75M |
| Net debt | -$30.54M | -$109.00M |
| Shares outstanding | 62.34M | 48.99M |
| Cash flow statement | ||
| Operating cash flow | -$177.96M | -$182.73M |
| Capital expenditure | $439,000 | $3.37M |
| Free cash flow | -$178.40M | -$186.10M |
| Investing cash flow | -$321.62M | $162.97M |
| Financing cash flow | $415.40M | -$59.49M |
| Depreciation & amortization | $14.76M | $12.64M |
| Stock-based compensation | $17.68M | $22.26M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.